麗珠醫藥(01513.HK)擬向麗珠微球公司增資2.09億元
格隆匯8月25日丨麗珠醫藥(01513.HK)公告,於2020年8月25日,公司董事會會議審議通過《關於變更部分募集資金投資項目實施主體暨向全資子公司增資的議案》,經與會董事認真審議,同意將“長效微球技術研發平台建設項目”實施主體由公司及麗珠集團麗珠製藥廠變更為公司及其全資子公司珠海市麗珠微球科技有限公司。
同意公司使用自有資金以貨幣方式向麗珠微球公司增資人民幣2.09億元,麗珠製藥廠以其擁有的微球製劑相關生產性資產(包含其使用募集資金形成的固定資產)並經合資格評估機構予以評估作價向麗珠微球公司增資1.39億元,雙方共計向麗珠微球公司增資3.48億元。本次增資完成後,麗珠微球公司註冊資本將變更為人民幣3.53億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.